Medium-vessel Vasculitis Presenting with Myalgia Following COVID-19 Moderna Vaccination: A Case Report

Shin-ichiro Ohmura; Yusuke Ohkubo; Ryuhei Ishihara; Yoshiro Otsuki; Toshiaki Miyamoto

doi:10.2169/internalmedicine.0293-22

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Medium-vessel Vasculitis Presenting with Myalgia Following COVID-19 Moderna Vaccination: A Case Report

Shin-ichiro Ohmura, Yusuke Ohkubo, Ryuhei Ishihara, Yoshiro Otsuki, Toshiaki Miyamoto

著者情報

キーワード: COVID-19, mRNA vaccine, autoimmune phenomena, medium-vessel vasculitis, myalgia

ジャーナルオープンアクセス早期公開

論文ID: 0293-22

DOI https://doi.org/10.2169/internalmedicine.0293-22

この記事には本公開記事があります。

The final version of this article is now available: Vol. 61 (2022), No. 22 pp. 3453-3457

詳細

抄録

Coronavirus disease 2019 (COVID-19) vaccines have been delivered worldwide to prevent the spread of the disease, and almost all Japanese have received the mRNA vaccines "BNT162b2" (Pfizer-Biotech) or "mRNA-1273" (Moderna). These vaccines have shown efficacy and safety with only minor adverse drug reactions. However, some patients develop severe adverse drug reactions, including autoimmune reactions. In addition, systemic vasculitis, mainly small-vessel vasculitis, following COVID-19 vaccination, has been reported. However, only a few investigators have reported medium-vessel vasculitis following vaccination. We herein report a case of medium-vessel vasculitis presenting with myalgia as the initial clinical manifestation following COVID-19 Moderna vaccination.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）